Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Infectious Disease (5)
- Medical Specialties (5)
- Virus Diseases (5)
- Bacteria (4)
- Bacterial Infections and Mycoses (4)
-
- Community Health and Preventive Medicine (4)
- Critical Care Nursing (4)
- Epidemiology (4)
- Health Information Technology (4)
- Influenza Humans (4)
- Internal Medicine (4)
- International Public Health (4)
- Nursing (4)
- Organisms (4)
- Public Health and Community Nursing (4)
- Pulmonology (4)
- Respiratory Tract Diseases (4)
- Sleep Medicine (4)
- Translational Medical Research (4)
- Viruses (4)
- Architecture (1)
- Chemistry (1)
- Civil and Environmental Engineering (1)
- Disorders of Environmental Origin (1)
- Engineering (1)
- Environmental Chemistry (1)
- Environmental Design (1)
Articles 1 - 6 of 6
Full-Text Articles in Medicine and Health Sciences
A Phase 1a/1b Clinical Trial Design To Assess Safety, Acceptability, Pharmacokinetics And Tolerability Of Intranasal Q-Griffithsin For Covid-19 Prophylaxis, Henry W. Nabeta, Maryam Zahin, Joshua L. Fuqua, Elizabeth D. Cash, Ingrid Leth, Michael Strauss, Jeanne Novak, Lin Wang, Angela Siegwald, Rachel A. Sheppard, Shesh N. Rai, Lisa C. Rohan, Sharon Hillier, Gerald W. Dryden, Kevin L. Potts, Kenneth E. Palmer
A Phase 1a/1b Clinical Trial Design To Assess Safety, Acceptability, Pharmacokinetics And Tolerability Of Intranasal Q-Griffithsin For Covid-19 Prophylaxis, Henry W. Nabeta, Maryam Zahin, Joshua L. Fuqua, Elizabeth D. Cash, Ingrid Leth, Michael Strauss, Jeanne Novak, Lin Wang, Angela Siegwald, Rachel A. Sheppard, Shesh N. Rai, Lisa C. Rohan, Sharon Hillier, Gerald W. Dryden, Kevin L. Potts, Kenneth E. Palmer
The University of Louisville Journal of Respiratory Infections
Background: The COVID-19 pandemic remains an ongoing threat to global public health. Q-Griffithsin (Q-GRFT) is a lectin that has demonstrated potent broad-spectrum inhibitory activity in preclinical studies in models of Nipah virus and the beta coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2.
Methods: Here, we propose a clinical trial design to test the safety, pharmacokinetics (PK), and tolerability of intranasally administered Q-GRFT for the prevention of SARS-CoV-2 infection as a prophylaxis strategy. The initial Phase 1a study will assess the safety and PK of a single dose of intranasally administered Q-GRFT. If found safe, the safety, PK, and tolerability of multiple doses …
Wastewater-Informed Public Health Intervention Playbook
Wastewater-Informed Public Health Intervention Playbook
Sustain Magazine
As the SARS-CoV-2 pandemic quickly spread from country to country and continent to continent in 2020, governments and scientists needed a way to track COVID-19 through populations in order to position public health interventions in the most impactful locations. Having a decision-based risk framework may help to guide policy creation that could minimize or prevent possible outbreaks and surges of infection within communities. The University of Louisville in partnership with Louisville’s Department of Public Health and Wellness tested this strategy in 2021 and 2022. This Wastewater-Informed Public Health Intervention Playbook describes the decisions and actions of that academic and public …
What About Anosmia From Covid-19 ?, Sharanya S E Santhi, Sara Elnour, Steven B Lippmann
What About Anosmia From Covid-19 ?, Sharanya S E Santhi, Sara Elnour, Steven B Lippmann
The University of Louisville Journal of Respiratory Infections
No abstract provided.
Treating Cytokine Storm In Patients With Covid-19, Ahmed Abdelhaleem, Deekshitha Turaka, Shameera Shaik Masthan, Steven B Lippmann
Treating Cytokine Storm In Patients With Covid-19, Ahmed Abdelhaleem, Deekshitha Turaka, Shameera Shaik Masthan, Steven B Lippmann
The University of Louisville Journal of Respiratory Infections
No abstract provided.
Covid-19, Vaccination, And Heart Transplantation, Forest W. Arnold
Covid-19, Vaccination, And Heart Transplantation, Forest W. Arnold
The University of Louisville Journal of Respiratory Infections
No abstract provided.
Are Antipyretic Medications Compatible With Sars-Cov-2 Vaccines?, Sharanya S E Santhi, Niguma Rayamajhi, Steven B Lippmann
Are Antipyretic Medications Compatible With Sars-Cov-2 Vaccines?, Sharanya S E Santhi, Niguma Rayamajhi, Steven B Lippmann
The University of Louisville Journal of Respiratory Infections
No abstract provided.